Perspective Therapeutics and PMV Pharma Provide Clinical Trial Updates
• Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.
• Perspective Therapeutics plans to initiate therapeutic dosing of PSV359, a FAP-α-targeted radiopharmaceutical, with potential study enrollment around mid-2025.
• PMV Pharmaceuticals' rezatapopt Phase 2 trial for TP53 Y220C-mutated solid tumors is on track, with an interim analysis expected by mid-2025.
• PMV Pharmaceuticals is collaborating with Foundation Medicine to develop a companion diagnostic for rezatapopt, a p53 Y220C reactivator.
© Copyright 2025. All Rights Reserved by MedPath